Loading...
•
Sep 30, 2021
Fulcrum Therapeutics Q3 2021 Earnings Report
Fulcrum Therapeutics made progress in advancing lead programs and reported positive interim results from the Phase 1 trial of FTX-6058.
Key Takeaways
Fulcrum Therapeutics reported financial results for the third quarter of 2021, highlighting progress in lead programs for FSHD and sickle cell disease and the potential of FTX-6058 as a functional cure for sickle cell disease. The company raised $144.2 million in gross proceeds extending cash runway into 2024.
On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease
Losmapimod update planned for Q1 2022
Raised $144.2 million in gross proceeds from August 2021 public offering, extending cash runway into 2024
Reported compelling data from Phase 1 trial of FTX-6058
Forward Guidance
Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...